The Effect of Channa Striata and Curcuma Supplementation on Nutritional Status, Interleukin-6 Levels, and Quality of Life in Patients With Breast Cancer.

NCT07722156 | Not Yet Recruiting

• 1 other identifier: USU Onchology Nutrition
• Study Type: interventional
• Target: 76
• Locations: 1 country
• Sites: 1

Brief Summary

Breast cancer is frequently accompanied by chronic inflammation, malnutrition, and reduced quality of life, all of which may compromise treatment response and clinical outcomes. Nutritional interventions with immunomodulatory and anti-inflammatory properties have the potential to improve these conditions. Channa striata is rich in high-quality protein, albumin, and essential amino acids that support nutritional recovery and tissue repair, while Curcuma contains curcumin, a bioactive compound with well-established anti-inflammatory and antioxidant effects. This study aims to evaluate the effect of combined Channa striata and Curcuma supplementation on nutritional status, serum interleukin-6 (IL-6) levels, and quality of life in patients with breast cancer undergoing treatment. The findings are expected to provide evidence for the use of this nutritional supplementation as a complementary strategy to improve clinical outcomes, reduce systemic inflammation, and enhance the overall well-being of breast cancer patients.

Conditions

Breast Cancer

Keywords

Breast cancer; Channa striata; Curcuma; Nutritional status; Interleukin-6 (IL-6); Quality of life; Nutritional supplementation; Inflammation.; Breast cancer, Channa striata Curcuma, Interleukin-6, Quality of life

Outcome Measures

Primary Outcomes (1)

• Nutritional status

  This study evaluated changes in BMI, following one month of Channa striata and Curcuma supplementation.

  baseline post intervention 4 weeks

Secondary Outcomes (1)

• interleukin - 6

  Baseline and 1 month after intervention

Study Arms (2)

experimental : channa striata and curcuma

EXPERIMENTAL

intervention group

Dietary Supplement: channa striata and curcuma

control

PLACEBO COMPARATOR

control group

Dietary Supplement: Maltodextrin (Placebo)

Interventions

channa striata and curcuma DIETARY_SUPPLEMENT

Participants in the intervention group received oral supplementation consisting of 5 g of Channa striata and 250 mg of Curcuma daily for one month, while participants in the control group received a maltodextrin placebo daily for the same duration.

experimental : channa striata and curcuma

Maltodextrin (Placebo) DIETARY_SUPPLEMENT

Participants in the control group received a placebo consisting of maltodextrin daily for one month.

control

Eligibility Criteria

• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Female patients with breast cancer aged ≥18 years who were undergoing chemotherapy.
• Patients with a body mass index (BMI) of 18-29 kg/m².
• Patients currently receiving chemotherapy for breast cancer.
• Patients with serum albumin levels of 2.0-3.5 g/dL.
• Patients who were able to consume oral food and were willing to participate in the study by providing written informed consent.

You may not qualify if:

• Patients with chronic kidney disease, renal failure, or kidney infection.
• Patients with a known allergy to fish or Channa striata (snakehead fish) albumin-derived products.
• Patients receiving other protein or amino acid supplements during the study period.
• Patients who were non-compliant or discontinued the intervention before completion of the study.

Sponsors & Collaborators

• DINA KEUMALA SARI: lead

Study Sites (1)

Nutrition Department

Medan, North Sumatera, Indonesia

Location

MeSH Terms

Conditions

Breast Neoplasms; Inflammation

Interventions

turmeric extract; maltodextrin

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Damayanti Tridah Ayu

CONTACT

628116816444; damayantitridahayu@gmail.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: SUPPORTIVE CARE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Prof

Study Record Dates

• First Submitted: July 15, 2026
• First Posted: July 23, 2026
• Study Start: August 1, 2026
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): January 31, 2027
• Last Updated: July 23, 2026

Record last verified: 2026-07

Locations

ID (1)